ES2130415T3 - Linfocitos t tumoricidas. - Google Patents

Linfocitos t tumoricidas.

Info

Publication number
ES2130415T3
ES2130415T3 ES94912545T ES94912545T ES2130415T3 ES 2130415 T3 ES2130415 T3 ES 2130415T3 ES 94912545 T ES94912545 T ES 94912545T ES 94912545 T ES94912545 T ES 94912545T ES 2130415 T3 ES2130415 T3 ES 2130415T3
Authority
ES
Spain
Prior art keywords
lymphocytes
cells
line
tumoricides
indicated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94912545T
Other languages
English (en)
Inventor
Herbert Jungfer
Heinrich Barchet
Winfried Albert
Ulrich Weidle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Application granted granted Critical
Publication of ES2130415T3 publication Critical patent/ES2130415T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

EL OBJETIVO DE LA INVENCION ES UNA LINEA DE CELULAS DE ANIMALES MAMIFEROS, DONDE SE EFECTUA UNA CO-CULTIVIZACION CON LINFOCITOS, DONDE SE EVITA UNA ESTIMULACION HALOGENA, CON LINFOCITOS ACTIVADOS DENTRO DE CELULAS TUMORICIDAS, PROCESO PARA LA ELABORACION DE LINFOCITOS T TUMORICIDAS MEDIANTE CO-CULTIVO DE LINFOCITOS CON LA LINEA DE CELULAS INDICADAS, LINFOCITOS T TUMORICIDAS OBTENIDOS MEDIANTE ESTE PROCESO Y LA UTILIZACION DE CELULAS INDICADAS PARA LA PRODUCCION DE UN AGENTE TERAPEUTICO UTILIZADO EN LA TERAPIA DE TUMORES.
ES94912545T 1993-03-31 1994-03-26 Linfocitos t tumoricidas. Expired - Lifetime ES2130415T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4310229 1993-03-31

Publications (1)

Publication Number Publication Date
ES2130415T3 true ES2130415T3 (es) 1999-07-01

Family

ID=6484173

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94912545T Expired - Lifetime ES2130415T3 (es) 1993-03-31 1994-03-26 Linfocitos t tumoricidas.

Country Status (9)

Country Link
US (1) US6576466B2 (es)
EP (1) EP0693120B1 (es)
JP (1) JP2980986B2 (es)
AT (1) ATE176683T1 (es)
AU (1) AU6505394A (es)
CA (1) CA2159443A1 (es)
DE (2) DE4410136A1 (es)
ES (1) ES2130415T3 (es)
WO (1) WO1994023014A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69739951D1 (de) 1996-03-04 2010-09-16 Calyx Bio Ventures Inc Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten
AU726198B2 (en) * 1996-03-04 2000-11-02 Targeted Genetics Corporation Modified rapid expansion methods ("modified-REM") for in vitro propagation of T lymphocytes
EP0910625A1 (de) * 1996-05-24 1999-04-28 Boehringer Mannheim Gmbh Verfahren zur kultivierung von zellen
CA2270117A1 (en) * 1996-10-30 1998-05-07 Roche Diagnostics Gmbh Process for producing tumoricide t-lymphocytes
US6251672B1 (en) 1997-05-15 2001-06-26 Gsf-Forschungszentrum Fur Umwelt Und Gesundheit Culturing mammalian cells in contact with cell surface proteins
US6579857B1 (en) * 1999-06-11 2003-06-17 Evanston Northwestern Healthcare Research Institute Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
CA2490401A1 (en) * 2002-06-28 2004-01-08 Xcyte Therapies, Inc. Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20050084967A1 (en) * 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US6797905B1 (en) * 2003-12-23 2004-09-28 Zippy Technology Corp. Rocker switch
JP6025707B2 (ja) * 2010-04-06 2016-11-16 エクソサイト セラピューティクス ピーティイー リミテッド 癌を治療する方法
WO2017088928A1 (de) 2015-11-27 2017-06-01 Technische Universität Ilmenau Verfahren und anordnung zur fermentation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3687014T2 (de) * 1985-05-01 1993-04-01 Asahi Chemical Ind Zum erkennen von tumoren faehige klonierte t-zelle und ein t-zellen-antigenrezeptor.
AU645488B2 (en) * 1989-02-21 1994-01-20 Terumo Corporation A process for the generation of proliferating CD4 lymphocytes
DE3923848C2 (de) 1989-07-19 1998-08-27 Nikolaus W Prof Dr Med Klehr Das Demaskierungstraining für autologe Immunozyten gegen maskierte Tumorzellen in vitro
EP0415666A1 (en) 1989-08-29 1991-03-06 Takeda Chemical Industries, Ltd. Composition for human cell cultivation and use thereof

Also Published As

Publication number Publication date
EP0693120B1 (de) 1999-02-10
US6576466B2 (en) 2003-06-10
ATE176683T1 (de) 1999-02-15
US20020039569A1 (en) 2002-04-04
WO1994023014A1 (de) 1994-10-13
JP2980986B2 (ja) 1999-11-22
DE4410136A1 (de) 1994-10-06
AU6505394A (en) 1994-10-24
JPH08503857A (ja) 1996-04-30
EP0693120A1 (de) 1996-01-24
CA2159443A1 (en) 1994-10-13
DE59407809D1 (de) 1999-03-25

Similar Documents

Publication Publication Date Title
ES2130415T3 (es) Linfocitos t tumoricidas.
ES512354A0 (es) "un procedimiento para formar dna doble filamentado".
DE19975031I2 (de) Verwendung von 4-Aminosalicyls{ure als entz}ndungshemmender Wirkstoff.
ES2054638T3 (es) Gen codificante de los factores humanos de estimulacion colonial.
ATE127694T1 (de) Lebende impfstoffe.
OA07419A (fr) Activateur de plamimogène de tissu humain, son procédé de production et composition pharmaceutique le contenant.
TNSN94035A1 (fr) Composition veterinaire
GEP20022656B (en) 2-(Purin-9-YL)-Tetrahydrofuran-3,4-Diol Derivatives
BR9814857A (pt) Processos para tratar leucemia, câncer sólido eleucemia, linfoma ou tumores sólidos em umhumano, e para fabricar uma composiçãofarmacêutica estéril, e, a respectiva composiçãofarmacêutica estéril
DE69215722D1 (de) Verstärker zur Ultraschalltherapie von Erkrankungen sowie diesen enthaltende flüssige Arzneimittelzusammensetzungen
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
GEP20033145B (en) Stem Cell Factor
ES482097A1 (es) Procedimiento para preparar derivados acilicos de carnitina.
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
DE3781182T2 (de) Tamoxifen zur topischen verwendung.
ES2038593T3 (es) Un procedimiento para preparar manosil-aglicona del antibiotico a 40926.
ES2001003A4 (es) Metodo para preparar polimeros de sulfometil-poliacrilamidas.
ES2185655T3 (es) Fracciones de acido aurintricarboxilico y analogos con actividad anti-angiogenica y metodos de uso.
HUT58037A (en) Process for producing n-2,3-butadienyl tri- and tetraaminoalkane derivatives
DE68902905T2 (de) 2-methyl-5-t-butyl-thiophenol, dessen herstellung und verwendung.
DE3684953D1 (de) Verwendung einer waessrigen chloritmatrix-loesung zur herstellung von arzneimitteln zur intravenoesen behandlung von tumoren.
ES8201535A1 (es) Un procedimiento para la preparacion de nuevos acil-deriva- dos de carnitina
ES8304058A1 (es) Un procedimiento para la preparacion del acido 3,7,11,15-tetrametil-2,4,6,10,14-hexadecapentaenoico.
ZA849576B (en) 1,7-diphenyl-3-methyllaza-7-cyano-8-methylnonane for use in the treatment of diseases
ATE25195T1 (de) Verwendung von d,l- und d-carazolol zur herstellung von antiglaukommitteln sowie arzneimittel, die d-carazolol enthalten.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 693120

Country of ref document: ES